IFM Due Inc is a spin-out of IFM Therapeutics Inc, an Abingworth portfolio company that was acquired by Bristol-Myers Squibb in 2017 for up to $2.3 billion. IFM Due is developing cGAS/STING antagonists for serious inflammatory and autoimmune diseases. These small molecules are designed to block excessive production of interferon and other pro-inflammatory cytokines with the first candidate expected to enter the clinic in 2020.

LocationBoston, Massachusetts
CEOGary Glick
Partner Vincent Miles